T Cell Activation and Cytokine Profile of Tuberculosis and HIV-Positive Individuals during Antituberculous Treatment and Efavirenz-Based Regimens

PLoS ONE

Volumn 8, Issue 6, 2013, Pages

  da Silva, Tatiana P ^a   Giacoia Gripp, Carmem B W ^a   Schmaltz, Carolina A ^b   Sant' Anna, Flavia M ^b   Rolla, Valeria ^b   Morgado, Mariza G ^a  

^a INSTITUTO OSWALDO CRUZ   (Brazil)

^b Funda??o Oswaldo Cruz   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

CD38 ANTIGEN; CYTOKINE; EFAVIRENZ; GAMMA INTERFERON; HLA DR ANTIGEN; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6; RIFAMPICIN; RNA DIRECTED DNA POLYMERASE INHIBITOR; TUBERCULOSTATIC AGENT; TUMOR NECROSIS FACTOR ALPHA; BENZOXAZINE DERIVATIVE;

ADULT; ARTICLE; BOOTSTRAPPING; CD3+ T LYMPHOCYTE; CD4 LYMPHOCYTE COUNT; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE PRODUCTION; EXTRAPULMONARY TUBERCULOSIS; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; IMMUNOCOMPROMISED PATIENT; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; MILIARY TUBERCULOSIS; MIXED INFECTION; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION; TUBERCULOSIS; VIRUS LOAD; CD4+ T LYMPHOCYTE; COMPLICATION; DRUG EFFECTS; GENE EXPRESSION REGULATION; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METABOLISM; MYCOBACTERIUM; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; ANTITUBERCULAR AGENTS; BENZOXAZINES; CD4 LYMPHOCYTE COUNT; CD4-POSITIVE T-LYMPHOCYTES; CYTOKINES; FEMALE; GENE EXPRESSION REGULATION; HIV INFECTIONS; HIV-1; HUMANS; LYMPHOCYTE ACTIVATION; MALE; MYCOBACTERIUM; PROSPECTIVE STUDIES; TREATMENT OUTCOME; TUBERCULOSIS; VIRAL LOAD;

EID: 84879200403     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0066095     Document Type: Article

References (37)

1. Appay V, Sauce D, (2008) Immune activation and inflammation in HIV-1 infection: causes and consequences. J Pathol 214: 231-241.
2. May MT, Sterne JA, Costagliola D, Sabin CA, Phillips AN, et al. (2006) HIV treatment response and prognosis in Europe and North America in the first decade of highly active antiretroviral therapy: a collaborative analysis. Lancet 368: 451-458.
3. Mocroft A, Phillips AN, Gatell J, Ledergerber B, Fisher M, et al. (2007) Normalisation of CD4 counts in patients with HIV-1 infection and maximum virological suppression who are taking combination antiretroviral therapy: an observational cohort study. Lancet 370: 407-413.
4. Lederman MM, Connick E, Landay A, Kuritzkes DR, Spritzler J, et al. (1998) Immunologic responses associated with 12 weeks of combination antiretroviral therapy consisting of zidovudine, lamivudine, and ritonavir: results of AIDS Clinical Trials Group Protocol 315. J Infect Dis 178: 70-79.
5. Zhang Z, Shang H, Jiang Y, Liu J, Dai D, et al. (2006) Activation and coreceptor expression of T lymphocytes induced by highly active antiretroviral therapy in Chinese HIV/AIDS patients. Chin Med J 119: 1966-1971.
6. Mahan C, Walusimbi M, Johnson D, Lancioni C, Charlebois E, et al. (2010) Tuberculosis Treatment in HIV Infected Ugandans with CD4 Counts >350 Cells/mm3 Reduces Immune Activation with No Effect on HIV Load or CD4 Count. PloS one 5: 1-6.
7. Olobo JO, Geletu M, Demissie A, Eguale T, Hiwot K, et al. (2001) Circulating TNF-alpha, TGF-beta, and IL-10 in Tuberculosis Patients and Healthy Contacts. Scand J Immunol 53: 85-91.
8. Rey AD, Mahuad CV, Bozza VV, Bogue C, Farroni MA, et al. (2007) Endocrine and cytokine responses in humans with pulmonary tuberculosis. Brain Behav Immun 21: 171-179.
9. Subramanyam S, Hanna LE, Venkatesan P, Sankaran K, Narayanan PR, et al. (2004) HIV alters plasma and M. tuberculosis-induced cytokine production in patients with tuberculosis. J Interferon Cytokine Res 24: 101-106.
10. Hernandez-Pando R, Orozco H, Aguilar D, (2009) Factors that deregulate the protective immune response in tuberculosis. Arch Immunol Ther Exp 57: 355-367.
11. Graziosi C, Gantt KR, Vaccarezza M, Demarest JF, Daucher M, et al. (1996) Kinetics of cytokine expression during primary human immunodeficiency virus type 1 infection. Proc Natl Acad Sci U S A. 93: 4386-4391.
12. Lawn SD, Butera ST, Folks TM, (2001) Contribution of Immune Activation to the Pathogenesis and Transmission of Human Immunodeficiency Virus Type 1 Infection. Clin Microbiol Rev 14: 753-777.
13. Stone SF, Price P, Keane NM, Murray RJ, French MA, (2002) Levels of IL-6 and soluble IL-6 receptor are increased in HIV patients with a history of immune restoration disease after HAART. HIV medicine 3: 21-27.
14. Worsley CM, Suchard MS, Stevens WS, Van Rie A, Murdoch DM, (2010) Multi-analyte profiling of ten cytokines in South African HIV-infected patients with Immune Reconstitution Inflammatory Syndrome (IRIS). AIDS Res Ther 7: 36.
15. Tadokera R, Meintjes G, Skolimowska KH, Wilkinson KA, Matthews K, et al. (2011) Hypercytokinaemia accompanies HIV-tuberculosis immune reconstitution inflammatory syndrome. Eur Respir J 37: 1248-1259.
16. Bruck Karen, Cunha ARC, Pereira GFM, Ravasi Giovanni, Carvalho LS, et al. (2011) Boletim Epidemiológico AIDS-DST. Aids 01.
17. Bacelar A, Sousa CES, Vaz CA, Gontijo CO, Henriques CMP, et al. (2012) Boletim Epidemiológico - Volume 43- Especial Tuberculose. Secretaria de Vigilância em Saúde 43.
18. Schmaltz CAS, Sant'Anna FM, Neves SC, Velasque LDS, Lourenço MC, et al. (2009) Influence of HIV infection on mortality in a cohort of patients treated for tuberculosis in the context of wide access to HAART, in Rio de Janeiro, Brazil. J Acquir Immune Defic Syndr 52: 623-628.
19. Meintjes G, Lawn SD, Scano F, Maartens G, French MA, et al. (2008) International Network for the Study of HIV-associated IRIS. Tuberculosis-associated immune reconstitution inflammatory syndrome: case definitions for use in resource-limited settings. Lancet Infect Dis. 8(8): 516-23.
20. Bentwich Z, Kalinkovich A, Weisman Z, (1995) Immune activation is a dominant factor in the pathogenesis of African AIDS. Immunol Today (16): 187-191.
21. Douek DC, Roederer M, Koup RA, (2009) Emerging concepts in the immunopathogenesis of AIDS. Ann Rev Med. 60: 471-84.
22. Goicoechea M, Smith DM, Liu L, May S, Tenorio AR, et al. (2006) Determinants of CD4+ T cell recovery during suppressive antiretroviral therapy: association of immune activation, T cell maturation markers, and cellular HIV-1 DNA. J infect dis. 194: 29-37.
23. Anselmi A, Vendrame D, Rampon O, Giaquinto C, Zanchetta M, et al. (2007) Immune reconstitution in human immunodeficiency virus type 1-infected children with different virological responses to anti-retroviral therapy. Clin Exp Immunol (150): 442-50.
24. Holub M, Klucková Z, Beneda B, Hobstová J, Huzicka I, et al. (2000) Changes in lymphocyte subpopulations and CD3+/DR+ expression in sepsis. Clin Microbiol Infect. 6: 657-60.
25. Kiran B, Cagatay T, Clark P, Kosar F, Cagatay P, et al. (2010) Can immune parameters be used as predictors to distinguish between pulmonary multidrug-resistant and drug-sensitive tuberculosis? Arch Med Sci. 6: 77-82.
26. Lancioni CL, Mahan CS, Johnson DF, Walusimbi M, Chervenak KA, et al. (2011) Effects of antiretroviral therapy on immune function of HIV-infected adults with pulmonary tuberculosis and CD4+ >350 cells/mm3. J Infect Dis 203(7): 992-1001.
27. Giacoia-Gripp CBW, Sales AM, Nery JADC, Santos-Oliveira JR, de Oliveira AL, et al. (2011) Evaluation of cellular phenotypes implicated in immunopathogenesis and monitoring immune reconstitution inflammatory syndrome in HIV/leprosy cases. PloS one 6: e28735.
28. Flynn BJL, Chan J, Triebold KJ, Dalton DK, Stewart TA, et al. (1993) An Essential Role for Interferon 7 in Resistance to Mycobacterium tuberculosis Infection. J Exp Med (1786): 2249-54.
29. de Castro Cunha RM, Kallas EG, Rodrigues DS, Nascimento Burattini M, Salomao R, (2005) Interferon-gamma and tumour necrosis factor-alpha production by CD4+ T and CD8+ T lymphocytes in AIDS patients with tuberculosis. Clin Exp Immunol 140: 491-497.
30. Kwan CK, Ernst JD, (2011) HIV and Tuberculosis: a Deadly Human Syndemic. Clin Microbiol Rev. 24: 351-376.
31. Bal AM, Lakhashe SK, Thakar MR, Tripathy SP, Paranjape RS, (2005) Dysregulation of proinflammatory and regulatory cytokines in HIV infected persons with active tuberculosis. Cytokine 30: 275-281.
32. Santos-Oliveira JR, Giacoia-Gripp CBW, Alexandrino de Oliveira P, Amato VS, Lindoso JÂL, et al. (2010) High levels of T lymphocyte activation in Leishmania-HIV-1 co-infected individuals despite low HIV viral load. BMC Infect Dis 10: 358.
33. Opal SM, DePalo VA, (2000) Anti-inflammatory cytokines. Chest 117(4): 1162-72.
34. Blanc FX, Sok T, Laureillard D, Borand L, Rekacewicz C, et al. (2011) Earlier versus Later Start of Antiretroviral Therapy in HIV-Infected Adults with Tuberculosis. N Engl J Med. Oct 20 365(16): 1471-81.
35. Pean P, Nerrienet E, Madec Y, Borand L, Laureillard D, et al. (2012) Natural killer cell degranulation capacity predicts early onset of the immune reconstitution inflammatory syndrome (IRIS) in HIV-infected patients with tuberculosis. Blood. 5 119(14): 3315-20.
36. Serra FC, Hadad D, Orofino RL, Marinho F, Lourenço C, et al. (2007) Immune reconstitution syndrome in patients treated for HIV and tuberculosis in Rio de Janeiro. Braz J Infect Dis. 11(5): 462-5.
37. Müller M, Wandel S, Colebunders R, Attia S, Furrer H, et al. (2010) Immune reconstitution inflammatory syndrome in patients starting antiretroviral therapy for HIV infection: a systematic review and meta-analysis. Lancet Infect Dis. 10(4): 251-61.